Here’s our monthly summary of product recalls, import alerts, consent decrees, and corporate integrity agreements. A busy month!
Here’s our monthly summary of product recalls, import alerts, consent decrees, and corporate integrity agreements. A busy month! Continue reading
by Barbara Unger, FDAzilla GMP Quality Expert and Editor-in-Chief of GMP Regulatory Intelligence
A consent decree agreement is an agreement filed in the US courts formalizing a voluntary agreement between two parties. Here we will address consent decree agreements between FDA and several pharmaceutical companies based on repeated failures to adequately address CGMP deficiencies. It is not an action taken on the basis of a single form 483, or a single warning letter. Generally, a series of events play out over time when critical inspection observations are not addressed and are identified in subsequent inspections. Frequently one or more warning letters are involved. Consent decree agreements often include fines, with the option for additional financial penalties if conditions to which the firm agrees are not met. Often these firms are required to use a 3rd party consultants to perform lot release. Firms operating under a consent decree agreement have largely lost their independence in GMP activities. Unlike Corporate Integrity Agreement which have a defined duration, firms must petition to have the consent decree agreement condition rescinded.
“Forget about actual warning letters. The cost of us receiving a moderately bad 483 is roughly $250,000.”
I heard this from a reputable Head of Manufacturing of one of the largest biopharma companies in the world. While most pharma and med device companies seems to learn quickly from everyone else’s mistakes, companies still occasionally get a “moderately bad” 483. And then what happens after that? Continue reading
The FDA is having a very busy year. Q1 saw a slew of approvals, policy changes, high-profile stories, enforcement activities, and personnel changes. Q2 was no different. Here are our top 30 stories on the FDA for Q2 of 2011.
The Big Stories of the Quarter
- The Drug Shortage: Some people say the FDA is inadvertently at fault. Some say the FDA prevented 38 close calls. Some say that the shortage is a niche business opportunity. There was also some chatter that the FTC take these drug shortages into account when looking at M&A.
- The Avastin Battle: back and forth, back and forth, the FDA and Roche have gone. Finally last week, the FDA rejected arguments from Roche/Genentech that its approved anti-cancer drug should continue as an approved therapy for advanced breast cancer. Now that the science round is over, let the politics round begin.
- The other Triad/H&P Industries shoe drops. The big MSNBC lead story in February was just the beginning. Here’s a good background post by PharmaLot. And finally, in June, the FDA issued the consent decree. Continue reading
by Tony Chen
The first quarter of 2011 proved to be a busy one for the FDA. We saw a deputy commissioner resign, a chemist charged for insider trading, a couple of big consent decrees, a big cancer drug approval, a big no-news on social media guidance, and more. Here’s our wrap-up of the key developments. Continue reading